Organization | Pavlov First Saint Petersburg State Medical University

Pavlov First Saint Petersburg State Medical University Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: St. Petersburg Russian Federation (1897)

Organization Overview

First Clinical Trial

2005

NCT00241995

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Acad. I.P. Pavlov First Saint-Petersburg State Medical University | First Pavlov State Medical University in St. Petersburg, Russia | First Pavlov State Medical University of St. Petersburg | First Saint-Petersburg Medical University | Pavlov First Saint-Petersburg State Medical University | R.M.Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University | RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University | Ryazan State Medical University named after academician I.P. Pavlov | St. Petersburg State Pavlov Medical University | The First St. Petersburg state medical University n.a. Acad. I. P. Pavlov

Active Ingredients

Drugs in Phase 4 Trials (1)

incobotulinumtoxinA (Xeomin) (1 trial)

Drugs in Phase 3 Trials (3)

dexpanthenol (Berocca) (1 trial)

naltrexone (revia) (2 trials)

xylometazoline (1 trial)

Drugs in Phase 2 Trials (27)

allogeneic hematopoietic stem cells (Hemacord) (2 trials)

allogeneic lymphocytes (1 trial)

allogeneic stem cells (2 trials)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

azacitidine (vidaza) (1 trial)

bendamustine (treanda) (5 trials)

busulfan (myleran) (5 trials)

carboplatin (paraplatin) (2 trials)

cyclophosphamide (cytoxan) (6 trials)

cytarabine (cytosar-u) (2 trials)

etoposide (vepesid) (1 trial)

fludarabine (fludara) (6 trials)

gemcitabine (gemzar) (1 trial)

haploidentical mononuclear cells (1 trial)

human fecal microbiota (Reybota) (2 trials)

ifosfamide (ifex) (1 trial)

melphalan (alkeran) (2 trials)

methylprednisolone (medrol) (1 trial)

mycophenolate (myfortic) (4 trials)

nalmefene (revex) (1 trial)

nivolumab (opdivo) (7 trials)

platelet lysate (1 trial)

rituximab (rituxan) (2 trials)

ruxolitinib (jakafi) (4 trials)

sildenafil (viagra) (1 trial)

tacrolimus (prograf) (4 trials)

tretinoin (Retin-A) (1 trial)

Drugs in Other Trials (12)

allogeneic bone marrow derived mesenchymal stem cell (1 trial)

diazepam (valium) (1 trial)

docetaxel (taxotere) (1 trial)

fluorouracil (efudex) (1 trial)

lamotrigine (lamictal) (1 trial)

leucovorin (1 trial)

levofloxacin (levaquin) (1 trial)

memantine (namenda) (1 trial)

neovasculgen (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (1 trial)

topiramate (topamax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Fissure in Ano (Phase 4)

Graft vs Host Disease (Phase 2)

Heroin Dependence (Phase 3)

Hodgkin Disease (Phase 2)

Immune System Diseases (Phase 2)

Leukemia (Phase 2)

Leukemia, Biphenotypic, Acute (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Multiple Myeloma (Phase 2)

Multiple Sclerosis (Phase 1)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Opioid-Related Disorders (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Preleukemia (Phase 2)

Primary Myelofibrosis (Phase 2)

Sclerosis (Phase 1)

Syndrome (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 30
# of Trial APIs: 43